Shares of Nightstar Therapeutics PLC (NASDAQ:NITE) have earned an average broker rating score of 1.00 (Strong Buy) from the five brokers that cover the company, Zacks Investment Research reports. Five investment analysts have rated the stock with a strong buy rating.

Analysts have set a one year consensus target price of $27.80 for the company and are forecasting that the company will post ($0.19) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Nightstar Therapeutics an industry rank of 158 out of 265 based on the ratings given to related companies.

Several equities analysts have recently weighed in on the stock. Chardan Capital assumed coverage on shares of Nightstar Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $40.00 price objective on the stock. Leerink Swann assumed coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They set an “outperform” rating and a $25.00 target price on the stock. Wedbush assumed coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They set an “outperform” rating and a $19.00 target price on the stock. Jefferies Group assumed coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They set a “buy” rating and a $25.00 target price on the stock. Finally, BMO Capital Markets assumed coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They set an “outperform” rating and a $30.00 target price on the stock.

Shares of Nightstar Therapeutics (NITE) traded up $0.88 during trading hours on Friday, hitting $14.09. 76,400 shares of the stock traded hands, compared to its average volume of 44,867. Nightstar Therapeutics has a 52-week low of $11.99 and a 52-week high of $24.93. The company has a market cap of $395.94 and a PE ratio of -28.18.

Several hedge funds have recently bought and sold shares of NITE. Ameriprise Financial Inc. purchased a new position in shares of Nightstar Therapeutics in the third quarter valued at $5,761,000. Chartwell Investment Partners LLC purchased a new position in Nightstar Therapeutics during the third quarter worth $3,995,000. Alyeska Investment Group L.P. purchased a new position in Nightstar Therapeutics during the third quarter worth $1,920,000. Sphera Funds Management LTD. purchased a new position in Nightstar Therapeutics during the third quarter worth $1,728,000. Finally, Nationwide Fund Advisors purchased a new position in Nightstar Therapeutics during the third quarter worth $1,196,000. 27.12% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/05/zacks-brokerages-set-27-80-target-price-for-nightstar-therapeutics-plc-nite.html.

Nightstar Therapeutics Company Profile

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Get a free copy of the Zacks research report on Nightstar Therapeutics (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.